

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**RECEIPT OF US\$30 MILLION UPFRONT PAYMENT UNDER
THE COLLABORATION, OPTION AND LICENSE AGREEMENT WITH
ASTRAZENECA FOR THE DEVELOPMENT OF siRNA DRUGS**

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 July 2026, in relation to the entering into of a collaboration, option and license agreement (the “**Agreement**”) between the Group and AstraZeneca (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, the Group entered into the Agreement with AstraZeneca in July to establish a strategic research and development collaboration, utilising the Group’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to develop novel small nucleic acid drug candidates.

The Board is pleased to announce that the Group has received the upfront payment of US\$30 million from AstraZeneca on 12 August 2026 under the terms of the Agreement. The receipt of this upfront payment marks the smooth advancement of the collaboration between both parties, benefiting the overall strategic layout of the Group and accelerating the development of the small nucleic acid pipeline.

The development, manufacturing and commercialisation of the relevant licensed products are subject to uncertainties. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. The Company will make further announcement(s) as and when appropriate to disclose material developments in relation to the Agreement.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 12 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.